Clinical Trials | January 11, 2026
Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Subscribe To Our Newsletter & Stay Updated
